CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 355 enrolled
Drug / intervention
Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradioldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00745901
NCT00745901Phase 4Completed
CompareCT.gov

An Open Label Study to Evaluate Cycle Control With Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) and Yaz (Drospirenone/Ethinyl Estradiol) in Healthy Sexually Active Females

Ortho-McNeil Janssen Scientific Affairs, LLC·interventional·Posted Sep 3, 2008·Updated Mar 19, 2019

In Brief

A Phase 4 clinical trial evaluating Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol for Contraception. Completed, enrolled 355 participants.

Detailed Summary

The purpose of this study in healthy sexually active females is to evaluate the cycle control with norgestimate/ethinyl estradiol versus drospirenone/ethinyl estradiol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 3, 2008
Enrollment StartMay 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.8 years ago

Interventions

Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradioldrug